J.P. Morgan Sticks to Its Sell Rating for GlaxoSmithKline (GSK)
J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.
GSK on Role of AI, Technology in R&D: Vanguards of Health Care
"We talk about the S-curve for technology and in the past we've said it can be 10 or 20 years before you reach the top. I think what's going to be really different about AI is that time frame is going ...
UBS Reaffirms Their Hold Rating on GlaxoSmithKline (GSK)
UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The ...
newtelegraphng1d
Multinationals Exit: Evaluating Asian Investors’ Resillience
ShareThe year 2024 etched an indelible mark on Nigeria’s economic history as over 20 highprofile multinational corporations, including Unilever Nigeria Plc, Procter & Gamble, GlaxoSmithKline Consumer ...
Hosted on MSN2d
GSK and University of Oxford partner for cancer vaccine research
GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme to explore ...
GSK's depemokimab under review in China and Japan for asthma, CRSwNP
GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...
Buy2d
GSK applications for sinus disease treatment accepted for review
(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...
FierceBiotech3d
GSK offers up to £50M to conduct cancer vaccine research with the University of Oxford
British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work ...